Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized Study of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) for Treatment of Chemotherapy Induced Neutropenia in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Receiving First-Line Chemotherapy

NCT00701870 is registered in ClinicalTrials.gov with Telik as lead sponsor.

NCT NCT00701870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00701870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized Study of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) for Treatment of Chemotherapy Induced Neutropenia in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Receiving First-Line Chemotherapy
Lead sponsor
Telik
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2008
Completion date
November 30, 2008
Enrollment
1 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer